title: The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma.
abstract: Despite improvements over the past decade in the overall survival of patients with indolent non-Hodgkin lymphomas, these lymphomas remain largely incurable with standard therapies. Immunochemotherapy with rituximab-based regimens has become a well-established standard of care in the primary and relapsed disease settings. The role of hematopoietic stem cell transplantation in indolent lymphoma has been defined by the adoption of this therapy largely in the relapse setting because randomized trials in the first-line setting have not shown survival advantages. Allogeneic stem cell transplantation has the possibility for cure because of the potential for immunologic graft-versus-lymphoma effect, but there are significant concerns regarding nonrelapse mortality. Autologous stem cell transplantation offers a safe treatment platform, but relapse remains a significant issue. The role of transplantation in the current treatment landscape of immunochemotherapy has not been conclusively proven, and randomized trials are lacking. This review summarizes the current relevant data regarding transplantation in indolent non-Hodgkin lymphoma and highlights the issues relevant to clinicians in the field.
authors.affiliation: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, and Department of Medicine, University of Toronto, Toronto, ON, Canada.
authors.forename: John
authors.identifier: 0000-0002-6117-320X
authors.initials: J
authors.lastname: Kuruvilla
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D019520:Living Donors; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000628:therapy*; D009381:Neoplasms, Radiation-Induced / Q000209:etiology / Q000517:prevention & control; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation / Q000009:adverse effects